News & Perspective

Nov 26, 2018

Nov 26, 2018

News Scan for Nov 26, 2018

E coli romaine source
Polio cases in 3 nations
H5N6 case in China
Small US flu increase

Mar 27, 2017

Mar 27, 2017

News Scan for Mar 27, 2017

MERS case
Avian flu in 3 nations
Meningitis in Nigeria
Preparedness spending

Oct 19, 2016

Oct 19, 2016

News Scan for Oct 19, 2016

E coli in beef
Avian flu outbreaks
Cholera funding
Healthcare-related infections
5-strain kids' vaccine

Aug 14, 2013

Aug 14, 2013
H5N1 color electron micro

Study: Technique adds 'kill switch' to modified flu viruses

A new molecular strategy could diffuse some of the controversy over lab-modified flu viruses.

May 10, 2013

May 10, 2013

Experts offer dim view of potential vaccine response to H7N9

If the H7N9 influenza virus now circulating in China evolves into a pandemic strain, the world is likely to have great difficulty providing adequate supplies of an effective vaccine in time to blunt its impact, according to a viewpoint article by three experts in the Journal of the American Medical Association (JAMA).

Apr 01, 2013

Apr 01, 2013

China reports three H7N9 infections, two fatal

(CIDRAP News) – Chinese health officials yesterday announced three severe respiratory infections, two of them fatal, from H7N9 influenza, a subtype that has not been known to infect humans before.

Jan 23, 2013

Jan 23, 2013

Research moratorium on modified H5N1 viruses ends

(CIDRAP News) – A year-long voluntary moratorium on research involving transmissible H5N1 avian flu viruses ended today with a letter from a group of scientists that supports resuming the work in countries that have addressed the biosafety issues involved.

Jan 17, 2012

Jan 17, 2012

WHO to lead talks on controversial H5N1 studies

(CIDRAP News) – A World Health Organization (WHO) official said the agency will play a role in leading discussions on issues related to controversial H5N1 avian influenza transmission studies, as more experts called for a further global discussion of the issues.

Jun 12, 2008

Jun 12, 2008

Baxter says cell-based H5N1 vaccine did well in trial

(CIDRAP News) – A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culture—a combination of techniques that entails some risk but may boost immune response and shorten production time.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»